Search

Author/Creator James, Joyce

3. An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia*. (3rd October 2017)

Authors:
Sanga, Madhu; James, Joyce; Marini, Joseph; Gammon, Guy; Hale, Christine; Li, Jianke
Journal:
Xenobiotica
Issue:
Volume 47:Number 10(2017)
Page Start:
856
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗